Inflammatory Bowel Diseases
MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025
MRM Health; Series B Funding; Microbiome therapeutics; Ulcerative colitis; Live Biotherapeutic Product (LBP); Biocodex; Treeline; Biotech fundraising; IBD therapy
Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program
Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Treatment Options
Omvoh, FDA approval, Crohn’s disease, inflammatory bowel disease, mirikizumab-mrkz, Eli Lilly
Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases
Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial
Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson
Mirikizumab Shows Superior Histologic Response in Crohn’s Disease Compared to Ustekinumab
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
FDA Approves TREMFYA (Guselkumab) for Moderately to Severely Active Ulcerative Colitis
TREMFYA, Guselkumab, FDA Approval, Ulcerative Colitis, Inflammatory Bowel Disease, Johnson & Johnson